Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more
Novo Nordisk agreed to acquire Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional cardiometabolic drug candidates.
Novo Nordisk agreed to acquire Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional cardiometabolic drug candidates.
APOBEC, genetic mutations that contribute to bladder cancer development, muscle-invasive bladder cancer (MIBC), APOBEC-type driver mutations, APOBEC3B expression after infection with BKPyV.
A nonprofit group is doing deals in Brazil and India to make low-cost CAR-T cell therapies widely available.
At least 224 diabetes patients have been harmed by a software error causing their insulin pumps to spontaneously shut down, the FDA said Wednesday.
Google on Wednesday unveiled an AI tool capable of predicting the structure and interaction of a vast universe of biomolecules.
Younger workers did gain significant benefit from the peer-to-peer program
Sam Chang engages with Arlene Siefker-Radtke to explore the transformative impact of erdafitinib in treating advanced and metastatic urothelial cancer. Dr. Siefker-Radtke illuminates the targeted…
Two congenitally deaf children can hear after being treated with a gene therapy, according to new data from an ongoing clinical trial.
Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data…
While the bird flu virus risk to the general public is still very low, the threat is more significant for farm workers in contact with…
The FDA nod means trial sponsors can use Apple Watch’s A-fib history as a secondary endpoint in trials without having to do additional work.